ARWR Arrowhead Pharmaceuticals, Inc.
$59.03▲ +0.08%
Healthcare
Other
After hours
$59.03▲ +0.00%
Oct 27, 4:42 PM ET
Volume 2.12M
Avg Volume (10D) 1.79M
Key Metrics & Fundamentals
Market Cap
$8.34B
P/E Ratio
–
Div Yield
0.00%
52W Range
37.06 - 95.49
% vs 50 MA
-17.41%
% vs 200 MA
-17.80%
RSI-14
36.9
MACD Histogram
+0.7000
Beta (1Y vs SPY)
1.61
Free Cash Flow
-$181.32M
Gross Rev
$75.25M
Gross Profit
$75.25M
EBITDA
-$147.68M
COGS
–
Operating Exp
$245.35M
Operating Income
-$170.09M
EBIT
-$170.09M
Pretax Income
-$178.91M
Net Income
-$194.28M
EPS (Diluted)
-1.36
Price & Volume History
Loading chart…
Recent News
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
Business Wire · Oct 27, 2026 11:36 AM ET
Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own
Simply Wall St. · Oct 23, 2026 10:09 PM ET
Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says
MT Newswires · Oct 16, 2026 12:01 PM ET
Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?
Simply Wall St. · Oct 16, 2026 5:09 AM ET
ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases
Zacks Small Cap Research · Oct 15, 2026 11:08 AM ET
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $109 From $63, Maintains Buy Rating
MT Newswires · Oct 15, 2026 10:33 AM ET
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study
MarketBeat · Oct 14, 2026 7:02 PM ET
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
Clinical Trials Arena · Oct 14, 2026 1:21 PM ET
Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut?
Insider Monkey · Oct 14, 2026 12:43 PM ET
Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know
Stocktwits · Oct 14, 2026 11:36 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ARWR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.